Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2017

25.05.2017 | Review Article

Therapy assessment in prostate cancer using choline and PSMA PET/CT

verfasst von: Francesco Ceci, Ken Herrmann, Boris Hadaschik, Paolo Castellucci, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Abstract

While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.
Literatur
1.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMed Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMed
3.
Zurück zum Zitat Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMed Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMed
4.
Zurück zum Zitat Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.CrossRefPubMed Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.CrossRefPubMed
5.
Zurück zum Zitat Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9.CrossRefPubMed Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9.CrossRefPubMed
6.
Zurück zum Zitat Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.CrossRefPubMed Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.CrossRefPubMed
7.
Zurück zum Zitat Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.CrossRefPubMedPubMedCentral Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.CrossRefPubMedPubMedCentral De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.CrossRefPubMed Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.CrossRefPubMed
10.
Zurück zum Zitat Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010;76:1072–6.CrossRefPubMedPubMedCentral Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010;76:1072–6.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7.CrossRefPubMedPubMedCentral Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.CrossRefPubMedPubMedCentral Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.CrossRefPubMedPubMedCentral Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Burgio SL, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.CrossRefPubMed Burgio SL, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.CrossRefPubMed
15.
Zurück zum Zitat Pezaro CJ, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.CrossRefPubMed Pezaro CJ, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.CrossRefPubMed
16.
Zurück zum Zitat Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016:1–38. doi:10.1200/JCO.2015.64.2702. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016:1–38. doi:10.​1200/​JCO.​2015.​64.​2702.
17.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
19.
Zurück zum Zitat Koh DM, et al. Whole-body diffusion-weighted MRI: ips, tricks, and pitfalls. AJR Am J Roentgenol. 2012;199:252–62.CrossRefPubMed Koh DM, et al. Whole-body diffusion-weighted MRI: ips, tricks, and pitfalls. AJR Am J Roentgenol. 2012;199:252–62.CrossRefPubMed
20.
Zurück zum Zitat Padhani AR, Lecouvet FE, Tunariu N. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of Multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71(1):81–92.CrossRefPubMedPubMedCentral Padhani AR, Lecouvet FE, Tunariu N. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of Multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71(1):81–92.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Ackerstaff E, Pflug BR, Nelson JB, et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599–603.PubMed Ackerstaff E, Pflug BR, Nelson JB, et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599–603.PubMed
22.
Zurück zum Zitat Graziani T, Ceci F, Castellucci P, et al. (11)C-choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43(11):1971–9.CrossRefPubMed Graziani T, Ceci F, Castellucci P, et al. (11)C-choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43(11):1971–9.CrossRefPubMed
23.
Zurück zum Zitat Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906–10.CrossRefPubMed Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906–10.CrossRefPubMed
24.
Zurück zum Zitat Ceci F, Castellucci P, Graziani T, et al. (11)C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43(1):84–91.CrossRefPubMed Ceci F, Castellucci P, Graziani T, et al. (11)C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43(1):84–91.CrossRefPubMed
26.
Zurück zum Zitat De Giorgi U, Caroli P, Scarpi E, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42(8):1276–83.CrossRefPubMed De Giorgi U, Caroli P, Scarpi E, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42(8):1276–83.CrossRefPubMed
27.
Zurück zum Zitat De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5(23):12448–58. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5(23):12448–58.
28.
Zurück zum Zitat Maines F, Caffo O, Donner D, et al. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016;12:333–42.CrossRefPubMed Maines F, Caffo O, Donner D, et al. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016;12:333–42.CrossRefPubMed
29.
Zurück zum Zitat Oprea-Lager DE, Kramer G, van de Ven PM, et al. Repeatability of quantitative 18F-Fluoromethylcholine PET/CT studies in prostate cancer. J Nucl Med. 2016;57(5):721–7.CrossRefPubMed Oprea-Lager DE, Kramer G, van de Ven PM, et al. Repeatability of quantitative 18F-Fluoromethylcholine PET/CT studies in prostate cancer. J Nucl Med. 2016;57(5):721–7.CrossRefPubMed
30.
Zurück zum Zitat Giovacchini G, Picchio M, Garcia-Parra R, et al. 11C-choline PET/CT predicts prostate cancer–specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233–41.CrossRefPubMed Giovacchini G, Picchio M, Garcia-Parra R, et al. 11C-choline PET/CT predicts prostate cancer–specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233–41.CrossRefPubMed
31.
Zurück zum Zitat Giovacchini G, Incerti E, Mapelli P, et al. [11C]choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2015;42:877–84.CrossRefPubMed Giovacchini G, Incerti E, Mapelli P, et al. [11C]choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2015;42:877–84.CrossRefPubMed
32.
Zurück zum Zitat Kwee SA, Lim J, Watanabe A, et al. Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med. 2014;55:905–10.CrossRefPubMedPubMedCentral Kwee SA, Lim J, Watanabe A, et al. Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med. 2014;55:905–10.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of Fluciclovine ((18)F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197(3 Pt 1):676–83.CrossRefPubMed Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of Fluciclovine ((18)F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197(3 Pt 1):676–83.CrossRefPubMed
34.
Zurück zum Zitat Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.CrossRefPubMed Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.CrossRefPubMed
35.
Zurück zum Zitat Barinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–70.CrossRefPubMedPubMedCentral Barinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–70.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5(1):66.CrossRefPubMedPubMedCentral Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5(1):66.CrossRefPubMedPubMedCentral
Metadaten
Titel
Therapy assessment in prostate cancer using choline and PSMA PET/CT
verfasst von
Francesco Ceci
Ken Herrmann
Boris Hadaschik
Paolo Castellucci
Stefano Fanti
Publikationsdatum
25.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3723-3

Weitere Artikel der Sonderheft 1/2017

European Journal of Nuclear Medicine and Molecular Imaging 1/2017 Zur Ausgabe